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Branched-chain 2-methyl fatty acids are derived from abundant dietary lipids and cholesterol. β-
Oxidation of these lipids requires S-methyl groups, but those with R-methyl groups are common. α-
Methylacyl-CoA racemase (AMACR; P504S) catalyses chiral inversion, enabling metabolism. The 
enzyme is also important for conversion of the R- enantiomers of ibuprofen and related drugs to their 
pharmacologically active S- enantiomers. The enzyme works by a deprotonation/reprotonation 
mechanism via an enolate intermediate. 
 
AMACR protein levels and activity are increased in all prostate cancers. Reduction of levels using siRNA 
causes prostate cancer cells to revert to a more normal phenotype, including restoration of androgen 
dependent growth. The enzyme is therefore a promising new drug target. However, development of this 
target has been hampered by the difficulties in measuring chiral inversion and the resulting lack of a 
convenient, high-throughput assay. Consequently, only three studies on inhibitors of AMACR have been 
reported since 2001. 
 
Incubation of novel substrates containing fluorine with active human recombinant AMACR 1A resulted 
in the formation of an unsaturated product. Negative controls containing inactive enzyme did not produce 
a significant level of unsaturated product. Incubation of the unsaturated product and fluoride with active 
enzyme did not result in the formation of substrate, showing that the elimination reaction was irreversible. 
Steady-state kinetic analysis of the reaction shows that elimination of this substrate is ca. 32 x more 
efficient than chiral inversion of S-2-methyldecanoyl-CoA, as judged by kcat/Km. This new reaction has 
potential uses for the development of a high-throughput assay for development of AMACR inhibitors. It 
may also all development of more convenient techniques for diagnosing and monitoring prostate cancer 
based on AMACR activity.  
 
 
 
 
  
